基质血管部分
间充质干细胞
祖细胞
干细胞
骨愈合
松质骨
间质细胞
细胞生物学
脂肪组织
人口
移植
生物
癌症研究
医学
免疫学
病理
解剖
内科学
环境卫生
作者
Matthias König,Daisy D. Canepa,Dieter Cadosch,Elisa A. Casanova,Michael Heinzelmann,Daniel Rittirsch,Michael Plecko,Sonja Hemmi,Hans‐Peter Simmen,Paolo Cinelli,Guido A. Wanner
出处
期刊:Cytotherapy
[Elsevier]
日期:2016-01-01
卷期号:18 (1): 41-52
被引量:34
标识
DOI:10.1016/j.jcyt.2015.10.002
摘要
Fractures with a critical size bone defect (e.g., open fracture with segmental bone loss) are associated with high rates of delayed union and non-union. The prevention and treatment of these complications remain a serious issue in trauma and orthopaedic surgery. Autologous cancellous bone grafting is a well-established and widely used technique. However, it has drawbacks related to availability, increased morbidity and insufficient efficacy. Mesenchymal stromal cells can potentially be used to improve fracture healing. In particular, human fat tissue has been identified as a good source of multilineage adipose-derived stem cells, which can be differentiated into osteoblasts. The main issue is that mesenchymal stromal cells are a heterogeneous population of progenitors and lineage-committed cells harboring a broad range of regenerative properties. This heterogeneity is also mirrored in the differentiation potential of these cells. In the present study, we sought to test the possibility to enrich defined subpopulations of stem/progenitor cells for direct therapeutic application without requiring an in vitro expansion.We enriched a CD146+NG2+CD45- population of pericytes from freshly isolated stromal vascular fraction from mouse fat tissue and tested their osteogenic differentiation capacity in vitro and in vivo in a mouse model for critical size bone injury.Our results confirm the ability of enriched CD146+NG2+CD45- cells to efficiently generate osteoblasts in vitro, to colonize cancellous bone scaffolds and to successfully contribute to regeneration of large bone defects in vivo.This study represents proof of principle for the direct use of enriched populations of cells with stem/progenitor identity for therapeutic applications.
科研通智能强力驱动
Strongly Powered by AbleSci AI